Feb 4 (Reuters) - Rezolute Inc RZLT.O:
REZOLUTE PROVIDES UPDATE ON ITS PHASE 3 SUNRIZE STUDY OF ERSODETUG FOR THE TREATMENT OF HYPOGLYCEMIA DUE TO CONGENITAL HYPERINSULINISM
REZOLUTE INC - SUNRIZE ENROLLMENT COMPLETION EXPECTED IN Q2 2025
REZOLUTE INC - DMC REVIEWED OPEN-LABEL ARM FOR INFANTS, TARGET DRUG CONCENTRATIONS SAFELY REACHED
REZOLUTE INC - DMC APPROVES INFANT ENROLLMENT INTO DOUBLE-BLIND STUDY
Source text: ID:nGNX9dD3TS
Further company coverage: RZLT.O